![Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions | Business Wire Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions | Business Wire](https://mms.businesswire.com/media/20210608005243/en/783357/4/teva_RGB_JPEG.jpg)
Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions | Business Wire
![Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS) Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)](https://mma.prnewswire.com/media/1019389/Teva_Canada_Limited_Teva_Canada_Announces_the_Launch_of_a_Bioequ.jpg?w=500)
Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Teva Pharmaceutical Industries Ltd. - On Thursday May 12, Doug Sommerville General Manager Teva Canada, John Jacobs GM for Teva Canada Innovation, Ben Gray VP, General Counsel, Bennett Lee and Houri Ohan
![Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions | Business Wire Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions | Business Wire](https://mms.businesswire.com/media/20210608005243/en/783357/23/teva_RGB_JPEG.jpg)
Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions | Business Wire
Teva Canada - Diversity and inclusion is a way of life at Teva Canada. Our Senior Director of Regulatory Affairs, Mathi Mathivanan, sums up our commitment to these ideals: “Our employees come
![Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease](https://mma.prnewswire.com/media/686979/Teva_Canada_Limited_Teva_Canada_Announces_the_Launch_of_Teva_Cyc.jpg?w=500)
Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease
Teva Canada - At Teva Canada, we're striving to build a workforce that is representative of the communities we serve and the world at large. We have a shared responsibility to provide
Canadian Trademarks Details: TEVA SOURCE & Colour Design — 1386807 - Canadian Trademarks Database - Intellectual property and copyright - Canadian Intellectual Property Office - Innovation, Science and Economic Development Canada
![Teva Canada Announces the Launch of a Generic Version of (PR)Abilify®, (PR) Teva-Aripiprazole Tablets for the treatment of Schizophrenia | Markets Insider Teva Canada Announces the Launch of a Generic Version of (PR)Abilify®, (PR) Teva-Aripiprazole Tablets for the treatment of Schizophrenia | Markets Insider](https://mma.prnewswire.com/media/740720/Teva_Canada_Limited_Teva_Canada_Announces_the_Launch_of_a_Generi.jpg)